Sarah Cannon Research Institute’s Post

ESMO 2023 <Novatis> Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM(INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy setting for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). New analysis of key subgroups of clinical interest from NATALEE reinforces the potential of Kisqali®(ribociclib) plus endocrine therapy (ET) to consistently reduce the risk of cancer recurrence across a broad population of patients with stage II and stage III HR /HER2- early breast cancer, including those with no nodal involvement. https://lnkd.in/gxtcs8aA

See our latest data at #GI24 to learn more about our research in gastrointestinal #cancer

Novartis announced groundbreaking results from the #NETTER-2 trial, showing #Lutathera plus #octreotide significantly extends median progression-free survival to 22.8 months and reduces disease progression or death by 72% in advanced #gastroenteropancreatic #neuroendocrine #tumors (#GEPNETs). The study's findings, presented at the #ASCO 2024 #Gastrointestinal #Cancer Symposium, mark the first successful use of #radioligand therapy (RLT) as a first-line treatment. Jeff Legos, Global Head of #Oncology Development at Novartis, highlighted the broader implications of these results. He pointed, “This is the first positive Phase III trial of a #radioligandtherapy in the first-line setting, and the overall efficacy and safety results are amongst the most clinically relevant observed to date in this kind of advanced cancer, addressing a significant unmet need for patients with newly diagnosed advanced GEP-NETs.” https://lnkd.in/dbtRgrt8

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial https://lnkd.in/eK7zPfx7

Our latest research article is now published online in Oncogene. We demonstrate how cancer-associated fibroblasts within the tumor microenvironment are selectively altering breast cancer signalling in response to the hormone Estrogen, paving their way to therapy resistance. We go further to highlight signalling pathways involved in this cross-talk by utilizing a functional drug screen. Thanks to all the other authors in making this a reality. https://lnkd.in/dbcjbjAm

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results https://lnkd.in/eCAASm6B

ESMO - European Society for Medical Oncology plenary session highlighted PFS rates of fuzuloparib alone or in combination with apatinib for HER2-negative metastatic breast cancer harboring germline BRCA mutations. https://lnkd.in/ejNATVx7 #bcsm #cancer #oncology